NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Abou-Setta AM, Mousavi SS, Spooner C, et al. First-Generation Versus Second-Generation Antipsychotics in Adults: Comparative Effectiveness [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2012 Aug. (Comparative Effectiveness Reviews, No. 63.)

Cover of First-Generation Versus Second-Generation Antipsychotics in Adults: Comparative Effectiveness

First-Generation Versus Second-Generation Antipsychotics in Adults: Comparative Effectiveness [Internet].

Show details

Appendix DList of Companion Studies

A total of 146 articles were companions to the included studies.

Addington DE, Mohamed S, Rosenheck RA, et al. Impact of second-generation antipsychotics and perphenazine on depressive symptoms in a randomized trial of treatment for chronic schizophrenia. J Clin Psychiatry. 2011;72(1):75–80. [PubMed: 20868641]
Andrezina R, Marcus RN, Oren DA, et al. Intramuscular aripiprazole or haloperidol and transition to oral therapy in patients with agitation associated with schizophrenia: sub-analysis of a double-blind study. Curr Med Res Opin. 2006;22(11):2209–19. [PubMed: 17076982]
Arango C, Breier A, McMahon R, et al. The relationship of clozapine and haloperidol treatment response to prefrontal, hippocampal, and caudate brain volumes. Am J Psychiatry. 2003;160(8):1421–7. [PubMed: 12900303]
Arango C, Summerfelt A, Buchanan RW. Olanzapine effects on auditory sensory gating in schizophrenia. Am J Psychiatry. 2003;160(11):2066–8. [PubMed: 14594761]
Ascher-Svanum H, Stensland M, Zhao Z, et al. Acute weight gain, gender, and therapeutic response to antipsychotics in the treatment of patients with schizophrenia. BMC Psychiatry. 2005;5:3. [PMC free article: PMC547901] [PubMed: 15649317]
Baymiller SP, Ball P, McMahon RP, et al. Serum glucose and lipid changes during the course of clozapine treatment: the effect of concurrent beta-adrenergic antagonist treatment. Schizophr Res. 2003;59(1):49–57. [PubMed: 12413642]
Baymiller SP, Ball P, McMahon RP, et al. Weight and blood pressure change during clozapine treatment. Clin Neuropharmacol. 2002;25(4):202–6. [PubMed: 12151907]
Bilder RM, Goldman RS, Volavka J, et al. Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder. Am J Psychiatry. 2002;159(6):1018–28. [PubMed: 12042192]
Boter H, Peuskens J, Libiger J, et al. Effectiveness of antipsychotics in first-episode schizophrenia and schizophreniform disorder on response and remission: an open randomized clinical trial (EUFEST) Schizophr Res. 2009;115(2–3):97–103. [PubMed: 19819114]
Boulay LJ. 2004. Contrasting the effects of haloperidol and olanzapine on attention and working memory in schizophrenia: a double-blind flexible dose study. [dissertation]
Bowden CL, Myers JE, Grossman F, et al. Risperidone in combination with mood stabilizers: a 10-week continuation phase study in bipolar I disorder. J Clin Psychiatry. 2004;65(5):707–14. [PubMed: 15163260]
Breier A, Buchanan RW, Waltrip RW, et al. The effect of clozapine on plasma norepinephrine: relationship to clinical efficacy. Neuropsychopharmacology. 1994;10(1):1–7. [PubMed: 8179790]
Breier A, Hamilton SH. Comparative efficacy of olanzapine and haloperidol for patients with treatment-resistant schizophrenia. Biol Psychiatry. 1999;45(4):403–11. [PubMed: 10071708]
Buchanan RW, Breier A, Kirkpatrick B, et al. Positive and negative symptom response to clozapine in schizophrenic patients with and without the deficit syndrome. Am J Psychiatry. 1998;155(6):751–60. [PubMed: 9619146]
Buchanan RW, Holstein C, Breier A. The comparative efficacy and long-term effect of clozapine treatment on neuropsychological test performance. Biol Psychiatry. 1994;36(11):717–25. [PubMed: 7858067]
Buckley PF, Goldstein JM, Emsley RA. Efficacy and tolerability of quetiapine in poorly responsive, chronic schizophrenia. Schizophr Res. 2004;(2–3):143–50. [PubMed: 15061246]
Bustillo JR, Buchanan RW, Irish D, et al. Differential effect of clozapine on weight: a controlled study. Am J Psychiatry. 1996;153(6):817–9. [PubMed: 8633697]
Chengappa KN, Goldstein JM, Greenwood M, et al. A post hoc analysis of the impact on hostility and agitation of quetiapine and haloperidol among patients with schizophrenia. Clin Ther. 2003;25(2):530–41. [PubMed: 12749512]
Chouinard G. Effects of risperidone in tardive dyskinesia: an analysis of the Canadian multicenter risperidone study. J Clin Psychopharmacol. 1995;15(1:Suppl 1):36S–44S. [PubMed: 7537286]
Citrome L, Volavka J, Czobor P, et al. Efficacy of ziprasidone against hostility in schizophrenia: post hoc analysis of randomized, open-label study data. J Clin Psychiatry. 2006;67(4):638–42. [PubMed: 16669729]
Cramer J, Rosenheck R, Xu W, et al. Detecting improvement in quality of life and symptomatology in schizophrenia. Schizophr Bull. 2001;27(2):227–34. [PubMed: 11354590]
Crawford AM, Beasley CM Jr, Tollefson GD. The acute and long-term effect of olanzapine compared with placebo and haloperidol on serum prolactin concentrations. Schizophr Res. 1997;26(1):41–54. [PubMed: 9376336]
Crespo-Facorro B, Carrasco-Marin E, Perez-Iglesias R, et al. Interleukin-12 plasma levels in drug-naive patients with a first episode of psychosis: effects of antipsychotic drugs. Psychiatry Res. 2008;158(2):206–16. [PubMed: 18243335]
Crespo-Facorro B, Rodriguez-Sanchez JM, Perez-Iglesias R, et al. Neurocognitive effectiveness of haloperidol, risperidone, and olanzapine in first-episode psychosis: a randomized, controlled 1-year followup comparison. J Clin Psychiatry. 2009;70(5):717–29. [PubMed: 19389335]
Crespo-Facorro B, Roiz-Santianez R, Perez-Iglesias R, et al. Effect of antipsychotic drugs on brain morphometry: a randomized controlled one-year followup study of haloperidol, risperidone and olanzapine. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32(8):1936–43. [PubMed: 18930104]
Crespo-Facorro B, Pérez-Iglesias R, Mata I, et al. Relapse prevention and remission attainment in first-episode non-affective psychosis. A randomized, controlled 1-year followup comparison of haloperidol, risperidone and olanzapine. J Psychiatr Res. 2011;45(6):763–9. [PubMed: 21106207]
Czobor P, Volavka J, Meibach RC. Effect of risperidone on hostility in schizophrenia. J Clin Psychopharmacol. 1995;15(4):243–9. [PubMed: 7593706]
Czobor P, Volavka J, Sheitman B, et al. Antipsychotic-induced weight gain and therapeutic response: a differential association. J Clin Psychopharmacol. 2002;22(3):244–51. [PubMed: 12006893]
Daumit GL, Goff DC, Meyer JM, et al. Antipsychotic effects on estimated 10-year coronary heart disease risk in the CATIE schizophrenia study. Schizophr Res. 2008;105(1–3):175–87. [PMC free article: PMC2614656] [PubMed: 18775645]
Docherty JP, Baker RA, Eudicone J, et al. Effect of aripiprazole versus haloperidol on PANSS Prosocial items in early-episode patients with schizophrenia. Schizophr Res. 2010;120(1–3):199–203. [PubMed: 20547037]
Dossenbach MR, Folnegovic-Smalc V, Hotujac L, et al. Double-blind, randomized comparison of olanzapine versus fluphenazine in the long-term treatment of schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2004;28(2):311–8. [PubMed: 14751428]
Emsley R, Rabinowitz J, Medori R. Time course for antipsychotic treatment response in first-episode schizophrenia. Am J Psychiatry. 2006;163(4):743–5. [PubMed: 16585455]
Emsley R, Turner HJ, Schronen J, et al. A single-blind, randomized trial comparing quetiapine and haloperidol in the treatment of tardive dyskinesia. J Clin Psychiatry. 2004;65(5):696–701. [PubMed: 15163258]
Emsley RA, Buckley P. Differential effect of quetiapine on depressive symptoms in patients with partially responsive schizophrenia. J Psychopharmacol. 2003;(2):210–5. [PubMed: 12870569]
Fakra E, Salgado-Pineda P, Besnier N, et al. Risperidone versus haloperidol for facial affect recognition in schizophrenia: findings from a randomized study. World J Biol Psychiatry. 2009;10(4:Pt 3):28. [PubMed: 17853271]
Gaebel W, Moller HJ, Buchkremer G, et al. Pharmacological long-term treatment strategies in first episode schizophrenia: study design and preliminary results of an ongoing RCT within the German Research Network on Schizophrenia. Eur Arch Psychiatry Clin Neurosci. 2004;254(2):129–40. [PubMed: 15146342]
Gaebel W, Riesbeck M, von Wilmsdorff M, et al. Drug attitude as predictor for effectiveness in first-episode schizophrenia: Results of an open randomized trial (EUFEST) Eur Neuropsychopharmacol. 2010;20(5):310–6. [PubMed: 20202800]
Gaebel W, Riesbeck M, Wolwer W, et al. Maintenance treatment with risperidone or low-dose haloperidol in first-episode schizophrenia: 1-year results of a randomized controlled trial within the German Research Network on Schizophrenia. J Clin Psychiatry. 2007;68(11):1763–74. [PubMed: 18052570]
Glynn SM, Marder SR, Liberman RP, et al. Supplementing clinic-based skills training with manual-based community support sessions: effects on social adjustment of patients with schizophrenia. Am J Psychiatry. 2002;159(5):829–37. [PubMed: 11986138]
Goldstein JM, Cohen LS, Horton NJ, et al. Sex differences in clinical response to olanzapine compared with haloperidol. Psychiatry Res. 2002;110(1):27–37. [PubMed: 12007591]
Gomez JC, Crawford AM. Superior efficacy of olanzapine over haloperidol: analysis of patients with schizophrenia from a multicenter international trial. J Clin Psychiatry. 2001;62(Suppl 11) [PubMed: 11232753]
Green AI, Lieberman JA, Hamer RM, et al. Olanzapine and haloperidol in first episode psychosis: two-year data. Schizophr Res. 2006;86(1–3):234–43. [PubMed: 16887334]
Green AI, Tohen MF, Hamer RM, et al. First episode schizophrenia-related psychosis and substance use disorders: acute response to olanzapine and haloperidol. Schizophr Res. 2004;66(2–3):125–35. [PubMed: 15061244]
Green MF, Marder SR, Glynn SM, et al. The neurocognitive effects of low-dose haloperidol: a two-year comparison with risperidone. Biol Psychiatry. 2002;51(12):972–8. [PubMed: 12062881]
Green MF, Marshall BD Jr, Wirshing WC, et al. Does risperidone improve verbal working memory in treatment-resistant schizophrenia? Am J Psychiatry. 1997;154(6):799–804. [PubMed: 9167507]
Hamilton SH, Edgell ET, Revicki DA, et al. Functional outcomes in schizophrenia: a comparison of olanzapine and haloperidol in a European sample. Int Clin Psychopharmacol. 2000;15(5):245–55. [PubMed: 10993126]
Hamilton SH, Revicki DA, Edgell ET, et al. Clinical and economic outcomes of olanzapine compared with haloperidol for schizophrenia: results from a randomized clinical trial. Pharmacoeconomics. 1999;(5):469–80. [PubMed: 10537964]
Hamilton SH, Revicki DA, Genduso LA, et al. Olanzapine versus placebo and haloperidol: quality of life and efficacy results of the North American double-blind trial. Neuropsychopharmacology. 1998;18(1):41–9. [PubMed: 9408917]
Harvey PD, Pappadopulos E, Lombardo I, et al. Reduction of functional disability with atypical antipsychotic treatment: a randomized long term comparison of ziprasidone and haloperidol. Schizophr Res. 2009;115(1):24–9. [PubMed: 19189878]
Harvey PD, Rabinowitz J, Eerdekens M, et al. Treatment of cognitive impairment in early psychosis: a comparison of risperidone and haloperidol in a large long-term trial. Am J Psychiatry. 2005;162(10):1888–95. [PubMed: 16199835]
Horowitz Terri Lynn. 2001. Comparative neuropsychological effects of clozapine, risperidone, and haloperidol in treatment-refractory schizophrenia. [dissertation]
Inada T, Yagi G, Miura S. Extrapyramidal symptom profiles in Japanese patients with schizophrenia treated with olanzapine or haloperidol. Schizophr Res. 2002;57(2–3):227–38. [PubMed: 12223254]
Jakovljevic M, Pivac N, Mihaljevic-Peles A, et al. The effects of olanzapine and fluphenazine on plasma cortisol, prolactin and muscle rigidity in schizophrenic patients: a double blind study. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31(2):399–402. [PubMed: 17126974]
Kane JM, Honigfeld G, Singer J, et al. Clozapine for the treatment-resistant schizophrenic: results of a US multicenter trial. Psychopharmacology (Berl) 1989;99(Suppl):60–3.
Kane JM, Kim E, Kan HJ, et al. Comparative utility of aripiprazole and haloperidol in schizophrenia: post hoc analysis of two 52-week, randomized, controlled trials. Appl Health Econ Health Policy. 2009;7(2):109–19. [PubMed: 19731968]
Keefe RS, Bilder RM, Davis SM, et al. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. Archives of General Psychiatry. 2007;64(6):633–47. [PubMed: 17548746]
Keefe RS, Seidman LJ, Christensen BK, et al. Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: a randomized, double-blind trial of olanzapine versus low doses of haloperidol. Am J Psychiatry. 2004;161(6):985–95. [PubMed: 15169686]
Keefe RS, Seidman LJ, Christensen BK, et al. Long-term neurocognitive effects of olanzapine or low-dose haloperidol in first-episode psychosis. Biol Psychiatry. 2006;59(2):97–105. [PubMed: 16140282]
Kelly DL, Conley RR. A randomized double-blind 12-week study of quetiapine, risperidone or fluphenazine on sexual functioning in people with schizophrenia. Psychoneuroendocrinology. 2006;31(3):340–6. [PubMed: 16198059]
Kelly DL, Conley RR. Thyroid function in treatment-resistant schizophrenia patients treated with quetiapine, risperidone, or fluphenazine. J Clin Psychiatry. 2005;66(1):80–4. [PubMed: 15669892]
Kern RS, Green MF, Marshall BD Jr, et al. Risperidone vs. haloperidol on reaction time, manual dexterity, and motor learning in treatment-resistant schizophrenia patients. Biol Psychiatry. 1998;44(8):726–32. [PubMed: 9798076]
Kern RS, Green MF, Marshall J, et al. Risperidone versus haloperidol on secondary memory: can newer medications aid learning? Schizophr Bull. 1999;25(2):223–32. [PubMed: 10416728]
Kinon BJ, Basson BR, Gilmore JA, et al. Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia. J Clin Psychiatry. 2001;(2):92–100. [PubMed: 11247108]
Kinon BJ, Roychowdhury SM, Milton DR, et al. Effective resolution with olanzapine of acute presentation of behavioral agitation and positive psychotic symptoms in schizophrenia. J Clin Psychiatry. 2001;62(Suppl 21) [PubMed: 11232746]
Krakowski M, Czobor P, Citrome L. Weight gain, metabolic parameters, and the impact of race in aggressive inpatients randomized to double-blind clozapine, olanzapine or haloperidol. Schizophr Res. 2009;110(1–3):95–102. [PubMed: 19269139]
Krakowski MI, Czobor P, Nolan KA. Atypical antipsychotics, neurocognitive deficits, and aggression in schizophrenic patients. J Clin Psychopharmacol. 2008;28(5):485–93. [PubMed: 18794642]
Krakowski Menahem I, Czobor P. A prospective longitudinal study of cholesterol and aggression in patients randomized to clozapine, olanzapine, and haloperidol. J Clin Psychopharmacol. 2010;30(2):198–200. [PubMed: 20520296]
Lee SM, Chou YH, Li MH, et al. Effects of haloperidol and risperidone on cerebrohemodynamics in drug-naive schizophrenic patients. J Psychiatr Res. 2008;42(4):328–35. [PubMed: 17412363]
Levine SZ, Rabinowitz J. Trajectories and antecedents of treatment response over time in early-episode psychosis. Schizophr Bull. 2010;36(3):624–32. [PMC free article: PMC2879688] [PubMed: 18849294]
Liberman RP, Gutkind D, Mintz J, et al. Impact of risperidone versus haloperidol on activities of daily living in the treatment of refractory schizophrenia. Compr Psychiatry. 2002;43(6):469–73. [PubMed: 12439835]
Lieberman JA, Tollefson GD, Charles Antipsychotic drug effects on brain morphology in first-episode psychosis. Archives of General Psychiatry. 2005;(4):361–70. [PubMed: 15809403]
Lindenmayer JP, Czobor PV. Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics. The American Journal of Psychiatry. 2003;(2):290–6. [PubMed: 12562575]
Lindenmayer JP, Czobor PV. Effects of atypical antipsychotics on the syndromal profile in treatment-resistant schizophrenia. J Clin Psychiatry. 2004;(4):551–6. [PubMed: 15119920]
Lindstrom E, von KL. Changes in single symptoms and separate factors of the schizophrenic syndrome after treatment with risperidone or haloperidol. Pharmacopsychiatry. 1994;27(3):108–13. [PubMed: 7521534]
McEvoy JP, Johnson J, Perkins D, et al. Insight in first-episode psychosis. Psychol Med. 2006;36(10):1385–93. [PubMed: 16740175]
McEvoy JP. Efficacy of risperidone on positive features of schizophrenia. J Clin Psychiatry. 1994;55(Suppl 21) [PubMed: 7520904]
McGurk SR, Green MF, Wirshing WC, et al. Antipsychotic and anticholinergic effects on two types of spatial memory in schizophrenia. Schizophr Res. 2004;68(2–3):225–33. [PubMed: 15099605]
Meyer JM, Davis VG, Goff DC, et al. Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: prospective data from phase 1. Schizophr Res. 2008;101(1–3):273–86. [PMC free article: PMC3673564] [PubMed: 18258416]
Miceli JJ, Tensfeldt TG, Shiovitz T, et al. Effects of oral ziprasidone and oral haloperidol on QTc interval in patients with schizophrenia or schizoaffective disorder. Pharmacotherapy. 2010;30(2):127–35. [PubMed: 20099987]
Milas DZ, Ljubin T. Some memory span functions and motor speed in schizophrenics treated with olanzapine versus fluphenazine. Psychiatr Danub. 1999;(1–2):55–9.
Miller DD, Caroff SN, Davis SM, et al. Extrapyramidal side-effects of antipsychotics in a randomized trial. Br J Psychiatry. 2008;(4):279–88. [PMC free article: PMC2801816] [PubMed: 18827289]
Moller HJ, Bauml J, Ferrero F, et al. Risperidone in the treatment of schizophrenia: results of a study of patients from Germany, Austria, and Switzerland. Eur Arch Psychiatry Clin Neurosci. 1997;247(6):291–6. [PubMed: 9477007]
Moller HJ, Muller H, Borison RL, et al. A path-analytical approach to differentiate between direct and indirect drug effects on negative symptoms in schizophrenic patients: a re-evaluation of the North American risperidone study. Eur Arch Psychiatry Clin Neurosci. 1995;245(1):45–9. [PubMed: 7540426]
Mossner R, Schuhmacher A, Kühn KU, et al. Functional serotonin 1A receptor variant influences treatment response to atypical antipsychotics in schizophrenia. Pharmacogenet Genomics. 2009;19(1):91–4. [PubMed: 18849890]
Penn DL, Keefe RS, Davis SM, et al. The effects of antipsychotic medications on emotion perception in patients with chronic schizophrenia in the CATIE trial. Schizophr Res. 2009;115(1):17–23. [PMC free article: PMC2765056] [PubMed: 19766459]
Perez-Iglesias R, Crespo-Facorro B, Amado JA, et al. A 12-week randomized clinical trial to evaluate metabolic changes in drug-naive, first-episode psychosis patients treated with haloperidol, olanzapine, or risperidone. J Clin Psychiatry. 2007;68(11):1733–40. [PubMed: 18052567]
Perez-Iglesias R, Crespo-Facorro B, Martinez-Garcia O, et al. Weight gain induced by haloperidol, risperidone and olanzapine after 1 year: findings of a randomized clinical trial in a drug-naive population. Schizophr Res. 2008;99(1–3):13–22. [PubMed: 18053689]
Perez-Iglesias R, Mata I, Pelayo-Teran JM, et al. Glucose and lipid disturbances after 1 year of antipsychotic treatment in a drug-naive population. Schizophr Res. 2009;107(2–3):115–21. [PubMed: 18993033]
Perez-Iglesias R, Vazquez-Barquero JL, Amado JA, et al. Effect of antipsychotics on peptides involved in energy balance in drug-naive psychotic patients after 1 year of treatment. J Clin Psychopharmacol. 2008;28(3):289–95. [PubMed: 18480685]
Perkins D, Lieberman J, Gu H, et al. Predictors of antipsychotic treatment response in patients with first-episode schizophrenia, schizoaffective and schizophreniform disorders. Br J Psychiatry. 2004;185:18–24. [PubMed: 15231551]
Perkins DO, Johnson JL, Hamer RM, et al. Predictors of antipsychotic medication adherence in patients recovering from a first psychotic episode. Schizophr Res. 2006;83(1):53–63. [PubMed: 16529910]
Perlick DA, Rosenheck RA, Kaczynski R, et al. Association of symptomatology and cognitive deficits to functional capacity in schizophrenia. Schizophr Res. 2008;99(1–3):192–9. [PubMed: 17851042]
Perlick DA, Rosenheck RA, Kaczynski R, et al. Impact of antipsychotic medication on family burden in schizophrenia: longitudinal results of CATIE trial. Schizophr Res. 2010;116(2–3):118–25. [PubMed: 19864114]
Perry PJ, Lund BC, Sanger T, et al. Olanzapine plasma concentrations and clinical response: acute phase results of the North American Olanzapine Trial. J Clin Psychopharmacol. 2001;21(1):14–20. [PubMed: 11199942]
Purdon SE, Woodward N. Procedural learning in schizophrenia after 6 months of double-blind treatment with olanzapine, risperidone, and haloperidol. Psychopharmacology (Berl) 2003;(3–4):390–7. [PubMed: 12827347]
Rabinowitz J, Davidson M. Risperidone versus haloperidol in long-term hospitalized chronic patients in a double blind randomized trial: a post hoc analysis. Schizophr Res. 2001;50(1–2):89–93. [PubMed: 11378317]
Rabinowitz J, Harvey PD, Eerdekens M, et al. Premorbid functioning and treatment response in recent-onset schizophrenia. Br J Psychiatry. 2006;189:31–5. [PubMed: 16816303]
Rabinowitz J, Hornik T, Davidson M. Rapid onset of therapeutic effect of risperidone versus haloperidol in a double-blind randomized trial. J Clin Psychiatry. 2001;62(5):343–6. [PubMed: 11411815]
Resnick SG, Rosenheck RA, Canive JM, et al. Employment outcomes in a randomized trial of second-generation antipsychotics and perphenazine in the treatment of individuals with schizophrenia. J Behav Health Serv Res. 2008;35(2):215–25. [PubMed: 18246429]
Revicki DA, Genduso LA, Hamilton SH, et al. Olanzapine versus haloperidol in the treatment of schizophrenia and other psychotic disorders: quality of life and clinical outcomes of a randomized clinical trial. Qual Life Res. 1999;(5):417–26. [PubMed: 10474283]
Rosenheck R, Chang S, Choe Y, et al. Medication continuation and compliance: a comparison of patients treated with clozapine and haloperidol. J Clin Psychiatry. 2000;61(5):382–6. [PubMed: 10847315]
Rosenheck R, Cramer J, Jurgis G, et al. Clinical and psychopharmacologic factors influencing family burden in refractory schizophrenia. J Clin Psychiatry. 2000;61(9):671–6. [PubMed: 11030488]
Rosenheck R, Dunn L, Peszke M, et al. Impact of clozapine on negative symptoms and on the deficit syndrome in refractory schizophrenia. Am J Psychiatry. 1999;156(1):88–93. [PubMed: 9892302]
Rosenheck R, Evans D, Herz L, et al. How long to wait for a response to clozapine: a comparison of time course of response to clozapine and conventional antipsychotic medication in refractory schizophrenia. Schizophr Bull. 1999;25(4):709–19. [PubMed: 10667741]
Rosenheck R, Lawson W, Crayton J, et al. Predictors of differential response to clozapine and haloperidol. Biol Psychiatry. 1998;44(6):475–82. [PubMed: 9777179]
Rosenheck R, Tekell J, Peters J, et al. Does participation in psychosocial treatment augment the benefit of clozapine? Archives of General Psychiatry. 1998;55(7):618–25. [PubMed: 9672052]
Rosenheck RA, Davis VG, Davis SM, et al. Can a nonequivalent choice of dosing regimen bias the results of flexible dose double blind trials? The CATIE schizophrenia trial. Schizophr Res. 2009;113(1):12–8. [PubMed: 19545976]
Saddichha SM. Diabetes and schizophrenia; effect of disease or drug? Results from a randomized, double-blind, controlled prospective study in first-episode schizophrenia. Acta Psychiatr Scand. 2008;(5):342–7. [PubMed: 18307585]
Saddichha SM. Effect of olanzapine, risperidone, and haloperidol treatment on weight and body mass index in first-episode schizophrenia patients in India: a randomized, double-blind, controlled, prospective study. J Clin Psychiatry. 2007;(11):1793–8. [PubMed: 18052574]
Saddichha S, Manjunatha N, Ameen S, et al. Metabolic syndrome in first episode schizophrenia: a randomized double-blind controlled, short-term prospective study. Schizophr Res. 2008;101(1–3):266–72. [PubMed: 18262771]
Sanger TM, Lieberman JA, Tohen M, et al. Olanzapine versus haloperidol treatment in first-episode psychosis. Am J Psychiatry. 1999;156(1):79–87. [PubMed: 9892301]
Schooler NR. Negative symptoms in schizophrenia: assessment of the effect of risperidone. J Clin Psychiatry. 1994 May 27;55(Suppl 5) [PubMed: 7520905]
Schuhmacher A, Mossner R, Quednow BB, et al. Influence of 5-HT3 receptor subunit genes HTR3A, HTR3B, HTR3C, HTR3D and HTR3E on treatment response to antipsychotics in schizophrenia. Pharmacogenet Genomics. 2009;19(11):843–51. [PubMed: 19794330]
Shi L, Namjoshi MA, Zhang F, et al. Olanzapine versus haloperidol in the treatment of acute mania: clinical outcomes, health-related quality of life and work status. Int Clin Psychopharmacol. 2002;17(5):227–37. [PubMed: 12177585]
Simpson GM, Lindenmayer JP. Extrapyramidal symptoms in patients treated with risperidone. J Clin Psychopharmacol. 1997;(3):194–201. [PubMed: 9169965]
Stahl SM, Malla A, Newcomer JW, et al. A post hoc analysis of negative symptoms and psychosocial function in patients with schizophrenia: A 40-week randomized, double-blind study of ziprasidone versus haloperidol followed by a 3-year double-blind extension trial. J Clin Psychopharmacol. 2010;30(4):425–30. [PubMed: 20571437]
Stauffer VL, Case M, Kinon BJ, et al. Early response to antipsychotic therapy as a clinical marker of subsequent response in the treatment of patients with first-episode psychosis. Psychiatry Res. 2011;187(1–2):42–8. [PubMed: 21168920]
Strakowski SM, Johnson JL, DelBello MP, et al. Quality of life during treatment with haloperidol or olanzapine in the year following a first psychotic episode. Schizophr Res. 2005;78(2–3):161–9. [PubMed: 15950436]
Stroup TS. Heterogeneity of treatment effects in schizophrenia. Am J Med. 2007;120(4:Suppl 1):26–31. [PubMed: 17403379]
Sugar CA, James GM, Lenert LA, et al. Discrete state analysis for interpretation of data from clinical trials. Med Care. 2004;42(2):183–96. [PubMed: 14734956]
Swanson JW, Swartz MS, Van Dorn RA, et al. Comparison of antipsychotic medication effects on reducing violence in people with schizophrenia. Br J Psychiatry. 2008;193(1):37–43. [PMC free article: PMC2801826] [PubMed: 18700216]
Swartz MS, Perkins DO, Stroup TS, et al. Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study. The American Journal of Psychiatry. 2007;(3):428–36. [PubMed: 17329467]
Swartz MS, Wagner HR, Swanson JW, et al. The effectiveness of antipsychotic medications in patients who use or avoid illicit substances: results from the CATIE study. Schizophr Res. 2008;100(1–3):39–52. [PubMed: 18191383]
Tamayo JM, Mazzotti G, Tohen M, et al. Outcomes for Latin American versus White patients suffering from acute mania in a randomized, double-blind trial comparing olanzapine and haloperidol. J Clin Psychopharmacol. 2007;27(2):126–34. [PubMed: 17414234]
Thompson PM, Bartzokis G, Hayashi KM, et al. Time-lapse mapping of cortical changes in schizophrenia with different treatments. Cereb Cortex. 2009;19(5):1107–23. [PMC free article: PMC2665155] [PubMed: 18842668]
Tohen M, Zhang F, Keck PE, et al. Olanzapine versus haloperidol in schizoaffective disorder, bipolar type. J Affective Disord. 2001;67(1–3):133–40. [PubMed: 11869760]
Tollefson GD, Sanger TM, Andersen SW. Depressive signs and symptoms in schizophrenia: a prospective blinded trial of olanzapine and haloperidol. 11th European College of Neuropsychopharmacology Congress; 1998. [PubMed: 9510219]
Tollefson GD, Sanger TM, Beasley CM, et al. A double-blind, controlled comparison of the novel antipsychotic olanzapine versus haloperidol or placebo on anxious and depressive symptoms accompanying schizophrenia. Biol Psychiatry. 1998;43(11):803–10. [PubMed: 9611669]
Tollefson GD, Sanger TM, Lu Y, et al. Depressive signs and symptoms in schizophrenia: a prospective blinded trial of olanzapine and haloperidol. Archives of General Psychiatry. 1998;55(3):250–8. [PubMed: 9510219]
Tollefson GD, Sanger TM. Negative symptoms: a path analytic approach to a double-blind, placebo- and haloperidol-controlled clinical trial with olanzapine. Am J Psychiatry. 1997;154(4):466–74. [PubMed: 9090332]
Tran PV, Tollefson GD, Sanger TM, et al. Olanzapine versus haloperidol in the treatment of schizoaffective disorder: acute and long-term therapy. Br J Psychiatry. 1999;174:15–22. [PubMed: 10211146]
Tunis SL, Croghan TW, Heilman DK, et al. Reliability, validity, and application of the medical outcomes study 36-item short-form health survey (SF-36) in schizophrenic patients treated with olanzapine versus haloperidol. Med Care. 1999;37(7):678–91. [PubMed: 10424639]
Umbricht DS, Wirshing WC, Wirshing DA, et al. Clinical predictors of response to clozapine treatment in ambulatory patients with schizophrenia. J Clin Psychiatry. 2002;63(5):420–4. [PubMed: 12019667]
Volavka J, Czobor P, Cooper TB, et al. Prolactin levels in schizophrenia and schizoaffective disorder patients treated with clozapine, olanzapine, risperidone, or haloperidol. J Clin Psychiatry. 2004;65(1):57–61. [PubMed: 14744169]
Volavka J, Czobor P, Nolan K, et al. Overt aggression and psychotic symptoms in patients with schizophrenia treated with clozapine, olanzapine, risperidone, or haloperidol. J Clin Psychopharmacol. 2004;24(2):225–8. [PubMed: 15206671]
Wilms G, Van OC, Baert AL, et al. Ventricular enlargement, clinical correlates and treatment outcome in chronic schizophrenic inpatients. Acta Psychiatr Scand. 1992;85(4):306–12. [PubMed: 1375802]
Wright P, Lindborg SR, Birkett M, et al. Intramuscular olanzapine and intramuscular haloperidol in acute schizophrenia: antipsychotic efficacy and extrapyramidal safety during the first 24 hours of treatment. Can J Psychiatry. 2003;48(11):716–21. [PubMed: 14733451]
Wright P, Meehan K, Birkett M, et al. A comparison of the efficacy and safety of olanzapine versus haloperidol during transition from intramuscular to oral therapy. Clin Ther. 2003;25(5):1420–8. [PubMed: 12867218]
Zhang XY, Zhou DF, Cao LY, et al. Changes in serum interleukin-2, -6, and -8 levels before and during treatment with risperidone and haloperidol: relationship to outcome in schizophrenia. J Clin Psychiatry. 2004;65(7):940–7. [PubMed: 15291683]
Zhang XY, Zhou DF, Cao LY, et al. Cortisol and cytokines in chronic and treatment-resistant patients with schizophrenia: association with psychopathology and response to antipsychotics. Neuropsychopharmacology. 2005;30(8):1532–8. [PubMed: 15886721]
Zhang XY, Zhou DF, Cao LY, et al. Prolactin levels in male schizophrenic patients treated with risperidone and haloperidol: a double-blind and randomized study. Psychopharmacology (Berl) 2005;178(1):35–40. [PubMed: 15289996]
Zhang XY, Zhou DF, Cao LY, et al. The interaction between superoxide dismutase and prolactin is involved in response to haloperidol and risperidone treatment in schizophrenia: a double-blind and randomized study. J Clin Psychopharmacol. 2006;26(1):103–5. [PubMed: 16415724]
Zhang XY, Zhou DF, Qi LY, et al. Superoxide dismutase and cytokines in chronic patients with schizophrenia: association with psychopathology and response to antipsychotics. Psychopharmacology (Berl) 2009;204(1):177–84. [PubMed: 19139851]
Zipursky RB, Christensen BK, Daskalakis Z, et al. Treatment response to olanzapine and haloperidol and its association with dopamine D receptor occupancy in first-episode psychosis. Can J Psychiatry. 2005;50(8):462–9. [PubMed: 16127964]
Zipursky RB, Gu H, Green AI, et al. Course and predictors of weight gain in people with first-episode psychosis treated with olanzapine or haloperidol. Br J Psychiatry. 2005;187:537–43. [PubMed: 16319406]
Zuo L, Luo X, Krystal JH, et al. The efficacies of clozapine and haloperidol in refractory schizophrenia are related to DTNBP1 variation. Pharmacogenet Genomics. 2009;19(6):437–46. [PMC free article: PMC2857717] [PubMed: 19369910]
PubReader format: click here to try


  • PubReader
  • Print View
  • Cite this Page
  • PDF version of this title (6.5M)

Related information

  • PMC
    PubMed Central citations
  • PubMed
    Links to pubmed

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...